Purespring secures $105m to start Phase I/II trial of IgAN gene therapy
Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to clinic.
Cytiva-Cell & Gene Therapy WP 2
How will cell & gene therapy manufacturing look in 10 years?
Spur Therapeutics to begin Phase III gene therapy trial in Gaucher disease
Advancing quality control measures vital for cell and gene therapy development
APAC leaps ahead in adoptive cell therapy space
NHS investment critical to drive cell and gene therapy research
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
Prime Medicine gets green light for trials of first-ever prime editing drug
